Skip to content

Luting Cements for Prefabricated Zirconia Crown Retention in Primary Anterior Teeth in Children

Comparison of Self-Adhesive Resin, Conventional Glass Ionomer, and Bioactive Resin-Modified Glass Ionomer Cements for Prefabricated Zirconia Crown Retention in Primary Anterior Teeth: A Randomized Controlled Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07611734
Enrollment
120
Registered
2026-05-28
Start date
2026-05-01
Completion date
2029-07-01
Last updated
2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Caries, Primary Tooth Restoration, Tooth Injuries

Keywords

Prefabricated Zirconia Crown, Luting Cement, Glass Ionomer Cement, Bioactive Cement, Self-Adhesive Resin Cement, Crown Retention

Brief summary

The goal of this clinical trial is to compare the long-term clinical performance of three different luting cements used to bond prefabricated zirconia crowns (PZCs) on primary front teeth in young children. The trial will determine whether any single cement offers superior retention, gum health, or marginal sealing compared to the others over a 3-year period. Main Questions: The study aims to answer the following: Are conventional glass ionomer cement (GIC), bioactive resin-modified glass ionomer cement (BioCem™), and self-adhesive resin cement (SARC) equivalent in retaining prefabricated zirconia crowns on primary incisors over 36 months? Do these cements differ in their effect on gingival health, plaque accumulation, or marginal discoloration around the cemented crown? Comparison: Researchers will compare three parallel groups of children whose primary incisors are restored with identical prefabricated zirconia crowns but cemented with one of the three different luting cements. Participants will: Receive a clinical and radiographic dental examination at screening. Undergo placement of one or more prefabricated zirconia crowns on primary anterior teeth using their randomly assigned cement. Return to the clinic for blinded follow-up evaluations at 12, 24, and 36 months for assessment of crown retention, gingival health, plaque, and marginal staining.

Detailed description

This prospective, parallel-group, three-arm, randomized controlled trial evaluates the long-term clinical performance of three commercially available luting cements when used to bond prefabricated zirconia crowns (PZCs) on primary anterior teeth in pediatric patients. Although PZCs are increasingly preferred over stainless steel crowns for anterior restorations due to their superior esthetics and biocompatibility, their retention relies entirely on the luting cement because of their passive fit and conservative preparation design. Comparative clinical evidence on cement performance in this specific anatomical and functional context remains limited. Trial Design: The trial is conducted at the Pediatric Dental Clinic of Qassim University, Riyadh, Saudi Arabia. Eligible children aged 2 to 7 years requiring full-coverage restoration of one or more primary incisors are randomized in a 1:1:1 ratio to one of three cement groups using a computer-generated randomization sequence. Allocation labels are reshuffled after each assignment to preserve equal group sizes. An independent outcome assessor is blinded to group allocation throughout the trial, and standardized cheek retractors are used to mask cement margins during evaluations. Operators cannot be blinded due to material-specific application protocols. Intervention Protocols: Tooth preparation follows standardized anterior-specific minimal reduction principles (1.0-1.5 mm incisal, 0.5-0.8 mm uniform labial, feather-edge proximal margins) under rubber dam isolation. NuSmile® prefabricated zirconia crowns are used for all participants. Cement application follows manufacturer instructions for each group: Group 1 (GIC): Fuji IX GP Extra (GC America) - tooth conditioned with 20% polyacrylic acid for 20 seconds, rinsed, gently air-dried; cement hand-mixed, loaded into crown, seated under finger pressure for 3 minutes. Group 2 (BioCem™): BioCem™ Universal BioActive Cement (NuSmile®) - tooth cleaned with pumice and water, rinsed, dried; cement auto-mixed into crown, seated, briefly light-cured (2-3 s) for excess removal, then fully light-cured 20 s per surface. Group 3 (SARC): RelyX™ Universal Resin Cement (3M) - tooth cleaned with pumice and water, rinsed, dried; cement loaded, crown seated, tack-cured 2-3 s, excess removed, full light-curing 20 s per surface. All crowns are placed by a single calibrated pediatric dentist. Post-cementation periapical radiographs verify marginal integrity. Parents receive standardized oral hygiene instructions and a 7-day course of 0.12% chlorhexidine mouthwash. Follow-Up and Safety: Clinical evaluations occur at baseline, 12, 24, and 36 months. Retention is assessed by visual/tactile examination with a sharp explorer and LED transillumination (DEXIS CariVu®). Failed crowns are recemented and excluded from subsequent analyses. Adverse events including soft-tissue irritation, crown fracture, debonding, and aspiration risk are continuously recorded. Statistical Methodology: Sample size was calculated using G\*Power 3.1.9.7 assuming a medium effect size (f = 0.25) for ANOVA, 90% power, and α = 0.05, yielding 28 participants per group; this was inflated to 40 per group (total 120) to accommodate an anticipated 30% attrition over 36 months. The primary retention outcome will be analyzed by Kaplan-Meier survival analysis with between-group comparison using the log-rank test, supplemented by Fisher's exact test for proportional retention and Cox proportional hazards regression for hazard ratios. Gingival Index and Plaque Index will be compared between groups by one-way ANOVA and within groups by repeated-measures ANOVA. Margin discoloration distribution will be compared by chi-square (with Cramér's V as effect size) and within-group transitions by McNemar's test. Significance is set at p \< 0.05. Analyses will follow an intention-to-treat principle, with per-protocol sensitivity analyses.

Interventions

PROCEDURECementation with Fuji IX GP Extra Glass Ionomer Cement

Cementation with Fuji IX GP Extra Glass Ionomer Cement Hand-mixed conventional glass ionomer luting cement applied per manufacturer protocol; crown seated under finger pressure for 3 minutes; excess removed after initial set.

PROCEDURECementation with BioCem™ Universal BioActive Cement

Cementation with BioCem™ Universal BioActive Cement Auto-mixed bioactive resin-modified luting cement applied per manufacturer protocol; brief tack-cure to facilitate excess removal followed by full light-curing for 20 seconds per surface.

PROCEDURECementation with RelyX™ Universal Resin Cement

Cementation with RelyX™ Universal Resin Cement Self-adhesive dual-cure resin luting cement applied per manufacturer protocol; tack-cured for 2-3 seconds for excess removal, followed by full light-curing for 20 seconds per surface.

Sponsors

Murad Alrashidi
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The outcome assessor performing all post-cementation clinical evaluations is blinded to group allocation. Standardized cheek retractors are used to mask crown margins. The statistical analyst is also blinded to group allocation until after the analysis dataset is locked.

Eligibility

Sex/Gender
ALL
Age
2 Years to 7 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy children aged 2 to 7 years 2. One or more primary maxillary or mandibular incisors requiring full-coverage restoration due to caries or trauma 3. Adequate remaining tooth structure following preparation, defined as greater than 50% of the clinical crown 4. Parent or legal guardian able and willing to provide written informed consent and to commit to the 36-month follow-up schedule

Exclusion criteria

1. Active periodontal disease at the index tooth, defined as a Löe Gingival Index score of 2 or higher 2. Parafunctional habits such as bruxism, severe thumb-sucking, or tongue-thrust documented at screening 3. Known allergy or hypersensitivity to zirconia, resin, glass ionomer, or any component of the assigned cement 4. Inconsistent oral hygiene, defined as less than twice-daily toothbrushing per parental report 5. Systemic disease affecting bone metabolism, tooth development, or wound healing 6. Current participation in another interventional dental clinical trial

Design outcomes

Primary

MeasureTime frameDescription
Crown Retention (Survival)Baseline, 12, 24, and 36 months post-cementationThe primary outcome is the cumulative retention of prefabricated zirconia crowns over a 36-month follow-up period. Retention is assessed by a single blinded examiner at each scheduled visit using two complementary methods: (a) visual/tactile inspection with a sharp dental explorer applied circumferentially along the crown margin to detect dislodgement, mobility, or marginal gap; and (b) LED transillumination using the DEXIS CariVu® system to detect cracks, debonding, or marginal microleakage. A crown is classified as "failed" (debonded) if any complete loss of cement seal, dislodgement, or detectable marginal gap is observed. Retention is reported as the proportion of crowns surviving at each time point and as the time-to-failure for survival analysis. Higher retention proportions and longer survival times indicate better clinical performance.

Secondary

MeasureTime frameDescription
Plaque Accumulation Measured by the Silness & Löe Plaque Index (1964)Baseline, 12, 24, and 36 months post-cementationPlaque accumulation at the gingival margin of each cemented crown is assessed using the Silness \& Löe Plaque Index. The same four sites per tooth (mesial, distal, buccal, lingual) are scored by a blinded examiner on a 4-point ordinal scale: 0 = no plaque; 1 = a film of plaque adhering to the free gingival margin, recognizable only by running a probe across the surface; 2 = moderate accumulation of soft deposits visible to the naked eye; 3 = abundance of soft matter. A mean PI score is calculated per tooth and per participant; the participant-level mean ranges from a minimum of 0 to a maximum of 3, with higher scores indicating greater plaque accumulation.
Gingival Health Measured by the Löe Gingival Index (1967)Baseline, 12, 24, and 36 months post-cementationGingival inflammation around each cemented crown is assessed at baseline and at every follow-up visit using the Löe Gingival Index (1967). A single blinded examiner scores four gingival sites per tooth (mesial, distal, buccal, and lingual) on a 4-point ordinal scale: 0 = no clinical inflammation (normal gingiva); 1 = mild inflammation (slight color change, slight edema, no bleeding on probing); 2 = moderate inflammation (redness, edema, glazing, bleeding on probing); 3 = severe inflammation (marked redness and edema, ulceration, tendency to spontaneous bleeding). A mean GI score is calculated per tooth and per participant; the participant-level mean therefore ranges from a minimum of 0 to a maximum of 3, with higher scores indicating worse gingival health.
Marginal Discoloration Measured by the Modified United States Public Health Service (USPHS) CriteriaBaseline (immediately post-cementation), 12, 24, and 36 monthsDiscoloration at the crown-tooth interface is evaluated under standardized LED operatory lighting (1,000-1,400 lux) without magnification using the modified USPHS criteria, supplemented by high-resolution intraoral photography with cross-polarized filters. Each crown is assigned one of four ordinal ratings: Alpha (A) = no visible discoloration (best outcome); Bravo (B) = slight discoloration confined to the margin, not penetrating internally; Charlie (C) = obvious discoloration penetrating along the margin; Delta (D) = severe discoloration with secondary caries or restoration failure (worst outcome). The outcome is reported as the proportion of crowns in each category at each time point, with a higher proportion of Alpha ratings indicating better marginal integrity.

Countries

Saudi Arabia

Contacts

CONTACTMURAD ALRASHIDI, BDS, MSC
MU.ALRASHIDI@qu.edu.sa+966 55 302 2773
PRINCIPAL_INVESTIGATORMURAD ALRASHIDI, BDS, MSC

Qassim University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 29, 2026